Rhythm Pharmaceuticals, Inc. reported its financial results for the third quarter ended September 30, 2026, with net product revenue from global sales of IMCIVREE reaching $92.1 million, representing a 29% increase from the prior quarter. The company's net loss attributable to co
Rhythm Pharmaceuticals, Inc. Reports Third Quarter 2026 Net Product Revenue of $92.1 million
Rhythm Pharmaceuticals, Inc. reported its financial results for the third quarter ended September 30, 2026, with net pro...
By Dhallo News · November 3, 2026 at 10:42 PM IST
Have feedback on this article?Report error or suggestion
